Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 3, 2000, Pages 313-316

  Snow, Barry J ^a   Vingerhoets, Francois J G ^a   Langston, J William ^c   Tetrud, James W ^c   Sossi, Vesna ^b   Calne, Donald B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TRIUMF   (Canada)

^c PARKINSON S INSTITUTE   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyrine (MPTP); Fluorodopa; Parkinson's disease; Positron emission tomography

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPA; FLUORINE 18;

ADULT; ARTICLE; CAUDATE NUCLEUS; CELL LOSS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADULT; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034060717     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.3.313     Document Type: Article

References (37)

1. Langston JW, Ballard PA, Tetrad JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
2. Burns RS, Chiueh CC, Markey SP, et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-50.
3. Stern Y, Tetrud JW, Martin WRW, et al. Cognitive change following MPTP exposure. Neurology 1990;40:261-4.
4. Vingerhoets FJG, Snow BJ, Tetrud JW, et al. Positron emission tomography evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994; 36:765-70.
5. Forno LS, DeLanney LE, Irwin I, et al. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv Neurol 1993;60:600-8.
6. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-80.
7. Elsworth JD, Deutch AY, Redmond DE, et al. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neurosci 1989;33:323-31.
8. Pifl C, Schingnitz G, Hornykiewicz O. The neurotoxin MPTP does not reproduce in the resus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett 1988; 92:228-33.
9. Alexander GM, Schwartzman RJ, Brainard L, et al. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res 1992;588:261-9.
10. Hantraye P, Varastet M, Peschanski M, et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neurosci 1993;53:169-78.
11. Pifl C, Schingnitz G, Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neurosci 1991;44:591-605.
12. Perez-Otano I, Oset C, Luquin MR, et al. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci Lett 1994;175:121-5.
13. Moratalla R, Quinn B, DeLanney LE, et al. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurptoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Nat Acad Sci USA 1992;89:3859-63.
14. German DC, Dubach M, Askari S, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neurosci 1988;24:161-74.
15. Elsworth JD, Deutch AY, Redmond DE, Jr, et al. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Res 1990;513: 320-4.
16. Garnett ES, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 1984;11:174-9.
17. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal[18F]-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-55.
18. Calne DB, Langston JW, Martin WRW, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-8.
19. Duvoisin RC. The evaluation of extrapyramidal disease. In: de Ajuriaguerra J, Gauthier G. Monoamines noyaux gris centraux et syndrome de Parkinson. Geneva: Georg and Cie SA, 1971:313-25.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;5:427-42.
21. Kinahan PE, Rogers JG. Analytic 3D image reconstruction using all detected events. IEEE Transactions on Nuclear Science 1989;36:964-8.
22. Cherry SR, Dahlbom M, Hoffman EJ. 3D PET using a conventional multislice tomograph. J Comput Assist Tomogr 1991;15:655-68.
23. Bailey DL, Meikle SR. A convolution-subtraction scatter correction method for 3D PET. Phys Med Biol 1994;39: 411-24.
24. Vingerhoets FJG, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994;35: 18-24.
25. 18F]-dopa PET data. J Neurol Neurosurg Psychiatry 1994;57:278-4.
26. Sawle GV, Brooks DJ, Marsden CD, et al. Corticobasal degeneration. Brain 1991;114:541-56.
27. Turjanski N, Lees AJ, Brooks DJ. Dopaminergic function in patients with posttraumatic parkinsonism: an 18F-dopa PET study. Neurology 1997;49:183-9.
28. Spokes EGS, Bannister R, Oppenheimer DR. Multiple system atrophy with autonomic failure. J Neurol Sci 1979;43: 59-62.
29. Irwin I, DeLanney LE, Forno LS, et al. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res 1990;531:242-52.
30. Hirsch EC. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol 1992;32:S88-93.
31. Hirsch E, Graybiel AM, Agid Y. Melanized dopaminergic neurons are differentially susceptable to degeneration in Parkinson's disease. Nature 1988;334:345-8.
32. Hirsch EC, Mouatt A, Thomasset M, et al. Expression of calbindin D28-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution in Parkinson's disease. Neurodegeneration 1992;1:83-93.
33. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-96.
34. Yamada T, McGeer PL, Baimbridge KG, et al. Relative sparing in Parkinson's disease of substantia nigia dopamine neurons containing calbindin-D28K. Brain Res 1990;525: 303-7.
35. German DC, Manaye K, Smith WK, et al. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-14.
36. Marshall JF, Navarrete RJ. Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment. Brain Res 1990;534:348-51.
37. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992; 581:283-91.